Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 115 of 1,261
  1. US 11999773

    Anti-BCMA chimeric antigen receptors

    Cartesian Therapeutics, Inc. Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  2. US 11998606

    Compounds and methods for selective proteolysis of glucocorticoid receptors

    The Board of Regents of the University of Texas System Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  3. US 11999683

    Lipocationic dendrimers and uses thereof

    The Board of Regents of the University of Texas System Β· Granted Jun 4, 2024 Β· Expires May 30, 2044

    granted
  4. AU 2022390453

    NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS

    ANGELINI PHARMA S P A [IT] Β· Granted May 30, 2024 Β· Expires May 25, 2044

    granted
  5. US 11993793

    Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene

    Precision BioSciences, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  6. US 11993660

    Chimeric polypeptides and methods of altering the membrane localization of the same

    Cell Design Labs, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  7. US 11992506

    Stem cell derived pancreatic islet differentiation

    Vertex Pharmaceuticals Incorporated Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  8. US 11992480

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  9. US 11992555

    Solid solution compositions and use in chronic inflammation

    Infirst Healthcare Limited Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  10. US 11993594

    IRAK inhibitors and method for making and using

    Rigel Pharmaceuticals, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  11. US 11993603

    Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereof

    CHINA PHARMACEUTICAL UNIVERSITY Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  12. US 11993580

    Methods of treating neurological disorders

    Neumora Therapeutics, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  13. US 11993658

    Anti-BCMA antibodies and treatment methods

    Sutro Biopharma, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  14. US 11993600

    Saturated spirocyclics as antiviral agents

    Enanta Pharmaceuticals, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  15. US 11992531

    C3-carbon linked glutarimide degronimers for target protein degradation

    C4 THERAPEUTICS, INC. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  16. US 11992519

    Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  17. US 11992523

    Method for producing chikungunya virus (CHIKV) virus-like particles comprising the C, E2, and E1 structural proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  18. US 11992514

    Ready-to-use bivalirudin compositions

    MAIA PHARMACEUTICALS, INC. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  19. US 11993569

    3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases

    Northwestern University Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  20. US 11993570

    Cationic lipids

    Takeda Pharmaceutical Company Limited Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  21. US 11993789

    Pichinde virus reverse genetics systems and methods of use

    Regents of the University of Minnesota Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  22. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  23. US 11993641

    Methods for modulating an immune response

    Cue Biopharma, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted
  24. US 11992528

    Compositions and methods for conjugating activatable antibodies

    CytomX Therapeutics, Inc. Β· Granted May 28, 2024 Β· Expires May 23, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.